Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyOscar Health Mild TBI Testing Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedOscar HealthPolicy N/A

    Serum Testing For Evidence of Mild Traumatic Brain Injury

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and reimbursement for blood, saliva, and cerebrospinal fluid biomarker testing and biomarker panels used to evaluate mild traumatic brain injury, subject to applicable benefit, authorization, medical necessity, documentation, and coding requirements.

    Policy Summary
    PayerOscar Health
    PolicySerum Testing For Evidence of Mild Traumatic Brain Injury
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 28, 2026
    Next Review DateN/A
    Key ActionSubmit accurate service documentation and code claims according to applicable industry-standard coding and billing guidelines.
    SourceLink
    POLICY UPDATE CHANGES

    Code 0698U was added to the Applicable CPT/HCPCS Procedure Codes section.

    3Concussion markers not meeting criteria
    2TBI biomarker panels not meeting criteria
    18+ yearsFDA-cleared patient age
    12 hoursFDA-cleared testing window

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    13-15FDA-cleared GCS range
    1CPT/HCPCS code added

    Coverage Criteria

    Mild traumatic brain injury biomarker testing

    The following services do not meet criteria because published scientific literature does not establish that the tests are required and beneficial for diagnosis and treatment.

    Services not meeting criteria

    • Concussion-marker testing: Measurement of concussion markers, including S100B, GFAP, or UCH-L1, in blood, saliva, and/or cerebrospinal fluid for evaluation of mild traumatic brain injury does not meet criteria.

      The policy applies this limitation to testing performed in any of these specimen types.

    • TBI biomarker panels: Panels designed to measure biomarkers of traumatic brain injury, including i-STAT TBI Plasma and Alinity i TBI, do not meet criteria.

    For evaluation of mild traumatic brain injury, measurement of concussion markers such as S100B, GFAP, or UCH-L1 in blood, saliva, and/or cerebrospinal fluid does not meet criteria.

    Panels designed to measure traumatic brain injury biomarkers, including i-STAT TBI Plasma and Alinity i TBI, do not meet criteria.

    These services do not meet criteria because available published scientific literature does not confirm that the testing is required and beneficial for diagnosis and treatment of the individual's illness.

    Covered Indications

    FDA-cleared intended use for evaluating suspected mild traumatic brain injury

    The FDA-cleared intended use is to aid evaluation when all of the following conditions are met, in combination with other clinical information.

    FDA-cleared intended use

    • Patient age: The patient is 18 years of age or older.≥ 18 years
    • Clinical presentation: The patient has suspected mild traumatic brain injury.

      The Glasgow Coma Scale score must also be within the FDA-cleared range.

    • Glasgow Coma Scale: The patient's Glasgow Coma Scale score is 13-15.13-15

    Not Covered Services

    Blood, saliva, and/or cerebrospinal fluid measurement of concussion markers, including S100B, GFAP, and UCH-L1, is not covered for evaluation of mild traumatic brain injury.

    Coding and Clinical Test Parameters

    Applicable CPT/HCPCS Procedure CodesCPT
    83516Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method.
    84999Qualitative or semiquantitative, multiple step method; unlisted chemistry procedure. Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCHL1), immunoassay, whole blood or plasma, individual components reported with the overall result of elevated or non-elevated based on threshold comparison. Proprietary test: i-STAT TBI; laboratory/manufacturer: Abbott Point of Care.
    0698UNeurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCHL1), immunoassay, serum or plasma, individual components reported with the overall result of positive or negative based on threshold comparison. Proprietary test: Alinity i TBI; laboratory/manufacturer: Abbott Laboratories.
    Applicable CPT/HCPCS Procedure CodesCPT/HCPCS
    0698UNeurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCHL1), immunoassay, serum or plasma, individual components reported with the overall result of positive or negative based on threshold comparison. Proprietary test: Alinity i TBI; laboratory/manufacturer: Abbott Laboratories.
    S100B serum level
    TestS100B serum level
    ThresholdLess than 0.1 μg/L
    TimingMeasured within 4 hours of injury
    S100B serum level
    TestS100B serum level
    ThresholdLess than 0.10 mg/L
    Sampling windowSampled within 6 hours of injury

    Provider and Billing Actions

    Documentation Required

    Submit accurate service documentation

    Submit accurate documentation of the services performed and code claims according to applicable industry-standard coding and billing guidelines.

    Denial Risk

    TBI biomarker testing does not meet criteria

    Claims for concussion-marker testing in blood, saliva, and/or cerebrospinal fluid, including S100B, GFAP, or UCH-L1, may be denied because these services do not meet the policy’s criteria. Panels designed to measure TBI biomarkers, including i-STAT TBI Plasma and Alinity i TBI, also do not meet criteria.

    Denial Risk

    Insufficient documentation or incorrect coding

    Background

    Traumatic brain injury results from external forces and may cause contusions, hematomas, diffuse axonal injury, cerebral edema, and other focal or diffuse brain injuries. Mild traumatic brain injury, also called concussion, involves a trauma-induced alteration in mental status and may occur with or without loss of consciousness. Biomarkers such as S100B, GFAP, and UCH-L1 have been investigated as diagnostic, prognostic, or monitoring adjuncts; however, concerns remain regarding their specificity and ability to predict recovery or post-concussion outcomes.

    Definitions and Abbreviations

    Traumatic brain injury (TBI)
    TermTraumatic brain injury (TBI)
    DefinitionPathologic injuries to the brain resulting from external forces or trauma.
    Examples of injuryMay include focal contusions, hematomas, diffuse axonal injury, and cerebral edema or swelling.
    Concussion
    TermConcussion
    DefinitionA trauma-induced alteration in mental status after a mild traumatic brain injury.
    Loss of consciousnessMay occur with or without loss of consciousness.
    Policy Summary
    PayerOscar Health
    PolicySerum Testing For Evidence of Mild Traumatic Brain Injury
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 28, 2026
    Next Review DateN/A
    Key ActionSubmit accurate service documentation and code claims according to applicable industry-standard coding and billing guidelines.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsNot Covered ServicesCoding and Clinical Test ParametersProvider and Billing ActionsBackgroundDefinitions and Abbreviations
  1. Timing of testing: Testing is performed within 12 hours of the injury.≤ 12 hours after injury
  2. Intended clinical use: The test is used with other clinical information to assess the need for radiologic imaging, including CT or MRI.

    The test result is associated with the presence or absence of acute traumatic intracranial lesions seen on a head CT scan.

  3. i-STAT TBI intended-use clinical criteria
    Patient ageAdults age 18 years or older
    Glasgow Coma ScaleGCS score 13-15
    Time from injuryWithin 12 hours of injury

    Claims may be denied or payment may be recouped when accurate service documentation is not submitted or applicable coding and billing guidelines are not followed.

    mTBI
    AbbreviationmTBI
    MeaningMild traumatic brain injury.
    Related conditionConcussion is a trauma-induced alteration in mental status after a mild TBI.
    CSF
    AbbreviationCSF
    MeaningCerebrospinal fluid.
    Policy contextBiomarker testing may involve blood, saliva, and/or cerebrospinal fluid.
    GFAP
    AbbreviationGFAP
    MeaningGlial fibrillary acidic protein.
    Test contextThe Abbott TBI tests measure GFAP and UCH-L1 in blood-based testing.
    S100B
    AbbreviationS100B
    MeaningS100 calcium-binding protein B.
    Clinical contextSerum S100B levels have been considered in mild TBI evaluation.
    UCH-L1
    AbbreviationUCH-L1
    MeaningUbiquitin C-terminal hydrolase-L1.
    Test contextThe Abbott TBI tests measure UCH-L1 and GFAP in blood-based testing.
    Laboratory-developed test (LDT)
    TermLaboratory-developed test (LDT)
    DefinitionA test developed and validated by an individual laboratory and performed in house.
    Regulatory contextLDTs are regulated by CMS as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88); FDA clearance or approval is not currently required for clinical use.